Gala Pharmaceuticals - B (01672): ASC30 once-daily oral tablet demonstrated good and differentiated pharmacokinetic characteristics in a multiple-dose escalation study in the United States.

The Zhtng Finance APP reported that Geli Pharmaceuticals-B (01672) announced that positive top-line pharmacokinetic (PK) data was obtained from a randomized, double-blind, placebo-controlled multiple dose escalation (MAD) study in obese subjects (Body Mass Index (BMI): 30-40 kg/m2) in the United States for ASC30 once-daily oral tablets. In Cohort 1 (20 mg) and Cohort 2 (40 mg) of the Ib phase MAD study, the drug exposure of ASC30 (area under the curve AUC0-24h) reached 3,560 ng.h/mL and 5,060 ng.h/mL at steady state, respectively. These drug exposure data were consistent with the average weight loss relative to baseline after placebo calibration: after 28 days of treatment, a 4.5% decrease in Cohort 1 (20 mg) and a 6.5% decrease in Cohort 2 (40 mg) were observed, indicating that higher drug exposure levels can result in more significant weight loss effects.